central materials laboratory testing manual 2000

Financial Statement Analysis/Business Valuation (ACC345).Business Law, Ethics and Social Responsibility (BUS 5115).Organic Chemistry Laboratory I (CHM2210L).Health-Illness Concepts Across the Lifespan I (NUR 1460C).Human Physiology Laboratory (BIOL 3120 ).New urine biomarkers are continually being added to the test menu. Urine testing is a part of Medpace’s safety testing and biomarker services. Urinalysis / Drug Screening / Urine Biomarkers Siemens Advia 2120i -Reticulocyte hemoglobin content (CHr) and % of hypochromic RBC for iron deficiency studies Key Instrumentation Stago Coagulation Platformsīeckman Coulter LH750 and LH780 – CBC and Auto-differentials Plasminogen Activator Inhibitor Type 1 Antigen (PAI-1) Tissue-type Plasminogen Activator Antigen (tPA) Plasminogen Activator Inhibitor Type 1 Activity Thrombin Activatable Fibrinolysis Inhibitor (TAFI)

Central Lab Services CBC and Differential (auto and manual) All four Medpace laboratory locations are NGSP Level 1 certified for Hemoglobin A1c testing, a key biomarker used in diabetes studies. Medpace’s central lab has a complete hematology test menu and an ever-expanding specialized coagulation test menu. Key Instrumentation Abbott Molecular m2000 systemĪpplied Biosystems SimpliAmp Thermal Cyclerīeckman Coulter Olympus AU Chemistry Series Medpace utilizes global standard operating procedures, and identical assay platforms, calibrators, and quality control material. Additional assays can be added to monitor testing specific to a clinical program. Ten split samples are analyzed weekly on the same day in all Medpace labs globally for analytes across all major platforms.

The program is performed weekly at each Medpace laboratory to provide continual monitoring of global consistency. This ensures lab data reflects the impact of a compound and not differences in testing practices. In order to ensure that all results generated globally are harmonized, Medpace labs has an extensive inter-laboratory comparison program. With the increasing complexity and global scale of many clinical trials, it is important to maintain testing harmonization among each Medpace laboratory.

Request for Information – Bioanalytical Assaysĭata from Medpace central laboratories has been key for assessing the safety, tolerability, and efficacy of new drugs in development.

Enhancing Patient Diversity in Clinical Trials.

Clinical and Regulatory Services for Medical Devices.

Central materials laboratory testing manual 2000